COVID-19 patients who were previously vaccinated with Prevnar 13 and/or Pneumovax should have a lower risk of contracting (or dying from) secondary bacterial pneumonia.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”